BiotechTube

GS-1720 + GS-4182 + Placebo to Match BVY + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match GS1720/GS-4182 FDC

Phase 2/3Active
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV-1-Infection

Conditions

HIV-1-Infection

Trial Timeline

Aug 20, 2024 → Jun 1, 2029

NCT ID
NCT06544733

About GS-1720 + GS-4182 + Placebo to Match BVY + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match GS1720/GS-4182 FDC

GS-1720 + GS-4182 + Placebo to Match BVY + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match GS1720/GS-4182 FDC is a phase 2/3 stage product being developed by Gilead Sciences for HIV-1-Infection. The current trial status is active. This product is registered under clinical trial identifier NCT06544733. Target conditions include HIV-1-Infection.

What happened to similar drugs?

12 of 19 similar drugs in HIV-1-Infection were approved

Approved (12) Terminated (3) Active (6)
✅B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboGilead SciencesApproved
✅B/F/TAFGilead SciencesApproved
✅Genvoya + Epclusa + BiktarvyGilead SciencesApproved
✅Switch to B/F/TAF + Continue current regimenGilead SciencesApproved
✅F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)Gilead SciencesApproved
✅Maraviroc + TruvadaGilead SciencesApproved
✅B/F/TAF + TDF/3TC/EFVGilead SciencesApproved

Hype Score Breakdown

Clinical
15
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06544733Phase 2/3Active

Competing Products

20 competing products in HIV-1-Infection

See all competitors
ProductCompanyStageHype Score
CVC 150 mg + CVC 300 mgAbbViePhase 2
35
18F-RaltegravirMerckPhase 1
36
ISL/LEN + Antiretroviral CombinationsMerckPhase 3
44
Delstrigo + KOCITAFMerckPhase 3
44
ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LENMerckPhase 3
44
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboGilead SciencesApproved
35
GS-3242 + BVY + Standard of CareGilead SciencesPhase 1
36
B/F/TAFGilead SciencesApproved
43
Genvoya + Epclusa + BiktarvyGilead SciencesApproved
39
GS-1720 + GS-4182 + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match BVY + Placebo to Match GS1720/GS-4182 FDCGilead SciencesPhase 2/3
42
Dapivirine + TruvadaGilead SciencesPhase 2
27
Bictegravir/emtricitabine/tenofovir alafenamideGilead SciencesPre-clinical
22
GS-9131 + BIC + TAF + ARV regimen + DRV + RTVGilead SciencesPhase 2
27
Bavtavirine + B/F/TAF + Standard of Care (Substudy 01) + GS-1720 + Standard of Care (Substudy 02) + GS-6212 + Standard of Care (Substudy 03)Gilead SciencesPhase 1
29
TruvadaGilead SciencesPhase 2
42
B/F/TAFGilead SciencesPhase 1
29
Switch to B/F/TAF + Continue current regimenGilead SciencesApproved
43
B/F/TAF + F/TAF + DTG + DTG Placebo + F/TAF Placebo + B/F/TAF PlaceboGilead SciencesPhase 3
40
Vesatolimod + VRC07523LS + CAP256V2LSGilead SciencesPhase 2
35
F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)Gilead SciencesApproved
50